CTOs on the Move

IsoPlexis

www.isoplexis.com

 
IsoPlexis is leading a new era of functional proteomics. By identifying our most proteomically active single cells (or "superhero cells") for the first time, IsoPlexis enables researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at the majority of leading U.S. comprehensive cancer centers.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.isoplexis.com
  • 35 NorthEast Industrial Road
    Branford, CT USA 06405
  • Phone: 475.221.8402

Executives

Name Title Contact Details

Funding

IsoPlexis raised $25M on 05/14/2019
IsoPlexis raised $20M on 01/09/2020
IsoPlexis raised $50M on 01/07/2021
IsoPlexis raised $85M on 01/07/2021

Similar Companies

Biomet Microfixation

Founded by Walter Lorenz more than thirty years ago, Biomet Microfixation manufactures a complete range of craniomaxillofacial products, including LactoSorb, the first completely resorbable fixation system available in the U.S. Other products include

Prologin Technologies Inc

Prologin Technologies Inc is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kirin Pharma USA

Kirin Pharma USA, Inc. is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biocentric Solutions

Biocentric Solutions, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Univercells

Univercells is a technology company offering novel biomanufacturing platforms, aimed at increasing the availability and affordability of biologics – recombinant proteins and vaccines - for all. Univercells designs innovative production processes to significantly decrease the size of the necessary equipment and facility, for a lower capital and operational cost. The company`s process intensification and integration technology entails smaller footprint and unit cost while offering flexible capabilities, from small to large batches. Deployment of affordable production units enables `in-country, for-country` biologics production, creating value for manufacturers and healthcare systems with cost efficiency and local supply while increasing patients` access to healthcare. Univercells was founded in 2013 by experienced entrepreneurs Hugues Bultot, CEO, and José Castillo, CTO, who bring close to 25 years of expertise in the biotechnology and life sciences sectors. Headquartered in Gosselies (Belgium), Univercells benefits from support from the Walloon region, and received €3 million from Takeda in 2015. Most recently, the company was awarded a $12 million grant from the Bill & Melinda Gates Foundation.